Davis Stephen's Form 4 filing
Acadia Pharmaceuticals Inc (ACAD) · filed Oct 6, 2023
- Accession no.
- 0001209191-23-052389
- Filed
- Oct 6, 2023
- Trade date
- Oct 5-6, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.13M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Davis StephenCIK 0001131146 | Director, Officer (CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 6, 2023 | Common Stock | MOption exerciseDisposed | −103,999 | $0.00 | $0 | 173,332 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
Referenced by the price of 1 transaction in Table I.
- F3
The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
Referenced by the price of 1 transaction in Table I.